Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Ed Ajootian who wrote (1196)	9/22/1998 6:00:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Ed, As is now evident, Sturza jumped off this bandwagon way too early! Agreed, but you do have to give Sturza credit for climbing on the bandwagon before there was much of a band at all. Here's an extract from a Reuter's article today on PFE and SGP: NEW YORK, Sept 22 (Reuters) - Shares of Pfizer Inc. (NYSE:PFE) jumped Tuesday on bargain hunting while Schering-Plough Corp. (NYSE:SGP) gained on the company's start of Phase III trials of a new formulation of its Claritin antihistamine, analysts said. ... Saks said Schering-Plough was helped Tuesday by delayed enthusiasm over an announcement Monday that the company had begun late-stage clinical trials of the antihistamine drug desloratadine months ahead of expectations. Schering-Plough has licensed worldwide rights to the drug from Sepracor Inc. (NASDAQ:SEPR). It is a chemically changed, or metabolite form, of Claritin. Saks said the newer drug, if eventually approved, is expected to have fewer side effects than Claritin. Moreover, he said it would enjoy U.S. patent protection to the year 2014 -- 10 years beyond the 2004 expiration of Claritin's U.S. patent --------- Peter